AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22617574 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation
Number of subjects: 236
Study 22617574 — intervention group
Group type: COMPARATOR
Intervention: No irrigation
Number of subjects: 236
Study 20076851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial delivery of autologous bone marrow mononuclear cells (BM-MNC)
Number of subjects: 100
Study 18095198 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.7 microg/kg loading, 10 microg bolus dose with 5 minutes lockout time)
Number of subjects: 120
Study 18095198 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.3 microg/kg loading, 20 microg bolus dose with 3 minutes lockout time)
Number of subjects: 120
Study 18095198 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution without analgesic)
Number of subjects: 120
Study 16001776 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, and beta‐adrenergic blockers
Number of subjects: 0
Study 16001776 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic implantable cardioverter defibrillator (ICD) therapy
Number of subjects: 0
Study 16001776 — intervention group
Group type: COMPARATOR
Intervention: Routine prophylactic use of ICDs
Number of subjects: 0
Study 12010228 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 151
Study 12010228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 9925529 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of mefloquine (25 mg/kg) on day 2 with food
Number of subjects: 120
Study 9925529 — intervention group
Group type: EXPERIMENTAL
Intervention: Split dose of mefloquine (15 mg/kg on day 2 and 10 mg/kg on day 3) with food
Number of subjects: 120
Study 9925529 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of mefloquine (25 mg/kg) on day 0 without food
Number of subjects: 120
Study 9925529 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of mefloquine (25 mg/kg) on day 2 without food
Number of subjects: 120
Study 7789044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal insulin delivery
Number of subjects: 6
Study 7789044 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin administration
Number of subjects: 6
Study 1419641 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 249
Study 1419641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 6236952 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel 0.125 mg
Number of subjects: 8
Study 6236952 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel 0.250 mg
Number of subjects: 8
Study 6236952 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel 0.500 mg
Number of subjects: 8
Study 6236952 — intervention group
Group type: EXPERIMENTAL
Intervention: Lynestrenol 5 mg
Number of subjects: 8
Study 31352573 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Number of subjects: 60
Study 31352573 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 60
Study 31352573 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 30232658 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin–Steroids–Epinephrine combination
Number of subjects: 0
Study 30232658 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine alone
Number of subjects: 0
Study 27903561 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) programme
Number of subjects: 80
Study 27903561 — intervention group
Group type: COMPARATOR
Intervention: Educational control
Number of subjects: 80
Study 23836299 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation programme including exercises and cognitive-behavioural therapy
Number of subjects: 130
Study 23836299 — intervention group
Group type: COMPARATOR
Intervention: Exercises alone (control group)
Number of subjects: 130
Study 22532074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunneled version of the website with less user control
Number of subjects: 668
Study 22532074 — intervention group
Group type: EXPERIMENTAL
Intervention: High user control version of the website (freedom of choice to skip pages)
Number of subjects: 668
Study 22532074 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to the website)
Number of subjects: 668
Study 20306079 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate concentration contrast medium
Number of subjects: 159
Study 20306079 — intervention group
Group type: COMPARATOR
Intervention: High concentration contrast medium
Number of subjects: 159
Study 17889126 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 1558
Study 17889126 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 1558
Study 16251074 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Aided Detection (CAD)
Number of subjects: 120
Study 16251074 — intervention group
Group type: COMPARATOR
Intervention: No CAD (before CAD)
Number of subjects: 120
Study 16251074 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD
Number of subjects: 120
Study 12153599 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen plus methyltestosterone (1.25 mg esterified oestrogen and 2.5 mg methyltestosterone)
Number of subjects: 0
Study 12153599 — intervention group
Group type: COMPARATOR
Intervention: Oestrogen only (1.25 mg esterified oestrogen)
Number of subjects: 0
Study 10199530 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-coated catheters
Number of subjects: 67
Study 10199530 — intervention group
Group type: COMPARATOR
Intervention: Uncoated control catheters
Number of subjects: 67
Study 7587977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine dependence with alcohol abuse (COC-ETOH group)
Number of subjects: 73
Study 7587977 — intervention group
Group type: COMPARATOR
Intervention: Cocaine dependence only (COC-only group)
Number of subjects: 73
Study 2145499 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% tea-tree oil gel
Number of subjects: 124
Study 2145499 — intervention group
Group type: COMPARATOR
Intervention: 5% benzoyl peroxide lotion
Number of subjects: 124
Study 154748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 40 microgram and salbutamol 200 microgram
Number of subjects: 24
Study 154748 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 microgram
Number of subjects: 24
Study 154748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 40 microgram
Number of subjects: 24
Study 154748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 40 microgram and salbutamol 200 microgram together
Number of subjects: 24
Study 31999862 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for diagnosing IgE-mediated food allergy
Number of subjects: 69
Study 31033434 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate (MTX)
Number of subjects: 90
Study 31033434 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 90
Study 28431003 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 153
Study 28431003 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose BMCs (hiBMCs)
Number of subjects: 153
Study 28431003 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose BMCs (loBMCs)
Number of subjects: 153
Study 28431003 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated high-dose BMCs (irradiated hiBMCs)
Number of subjects: 153
Study 28431003 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated low-dose BMCs (irradiated loBMCs)
Number of subjects: 153
Study 25849685 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 0
Study 25849685 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study 23811060 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone (BUP)
Number of subjects: 152
Study 23811060 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine-naloxone (DETOX)
Number of subjects: 152
Study 21889074 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated subjects with fixed orthodontic appliances
Number of subjects: 46
Study 21889074 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 19153741 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual otoscopy and 3D ossicular reconstruction
Number of subjects: 33
Study 19153741 — intervention group
Group type: COMPARATOR
Intervention: 2D images (HRCT)
Number of subjects: 33
Study 19153741 — intervention group
Group type: COMPARATOR
Intervention: HRCT and 2D reformatted images
Number of subjects: 33
Study 17120974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cha-em Thai mouthwash
Number of subjects: 67
Study 15047458 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (epoietin alpha and beta, darbepoietin-alpha, EPO)
Number of subjects: 30
Study 15047458 — intervention group
Group type: COMPARATOR
Intervention: No anti-anaemic treatment
Number of subjects: 30
Study 11380284 — intervention group
Group type: EXPERIMENTAL
Intervention: Proliferative phase
Number of subjects: 27
Study 11380284 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa treatment
Number of subjects: 27
Study 11380284 — intervention group
Group type: COMPARATOR
Intervention: Proliferative phase myometrium
Number of subjects: 27
Study 11380284 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa treated patients
Number of subjects: 27
Study 11380284 — intervention group
Group type: COMPARATOR
Intervention: Secretory phase
Number of subjects: 27
Study 8993821 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia infusion sleeve (AIS)
Number of subjects: 80
Study 8993821 — intervention group
Group type: COMPARATOR
Intervention: Standard sheath for vascular access
Number of subjects: 80
Study 8496514 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer teaching
Number of subjects: 50
Study 8496514 — intervention group
Group type: COMPARATOR
Intervention: Instructor teaching
Number of subjects: 50
Study 2894215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (mean daily dose 71 mg)
Number of subjects: 56
Study 2894215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin + Bendrofluazide
Number of subjects: 56
Study 2894215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin + Atenolol
Number of subjects: 56
Study 2894215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 2894215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 56
Study 29966855 — intervention group
Group type: EXPERIMENTAL
Intervention: Detached mindfulness intervention
Number of subjects: 52
Study 29966855 — intervention group
Group type: COMPARATOR
Intervention: Non-active control
Number of subjects: 52
Study 27075480 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise protocol for the foot-ankle for 8 weeks, with 1 directly supervised session and 3 remotely supervised sessions per week, followed by 10 months of web-enabled software supervision three times a week
Number of subjects: 111
Study 27075480 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 111
Study 27075480 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise protocol for the foot-ankle
Number of subjects: 111
Study 26580879 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (9 units)
Number of subjects: 20
Study 26580879 — intervention group
Group type: COMPARATOR
Intervention: AbobotulinumtoxinA (27 units)
Number of subjects: 20
Study 23776081 — intervention group
Group type: EXPERIMENTAL
Intervention: Medela Symphony (pump S)
Number of subjects: 71
Study 23776081 — intervention group
Group type: COMPARATOR
Intervention: Philips AVENT Twin electronic pump (pump A)
Number of subjects: 71
Study 20230606 — intervention group
Group type: EXPERIMENTAL
Intervention: SHARP-at work intervention
Number of subjects: 0
Study 20230606 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 18677023 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous growth hormone (GH) starting dose 2 microg/kg/d, increased to maximum dose of 6 microg/kg/d for 18 months.
Number of subjects: 56
Study 18677023 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 18 months.
Number of subjects: 56
Study 15933559 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) 50 mg/m for infants >28 days of age
Number of subjects: 44
Study 15933559 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) 25 mg/m for infants < or =28 days of age, escalated to 50 mg/m
Number of subjects: 44
Study 15933559 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) treatment
Number of subjects: 44
Study 15933559 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) treatment
Number of subjects: 44
Study 12868552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin‐clavulanic acid plus amikacin (TCA)
Number of subjects: 127
Study 12868552 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime plus amikacin (CFA)
Number of subjects: 127
Study 10392222 — intervention group
Group type: EXPERIMENTAL
Intervention: Instillation of 5 mL of normal saline before endotracheal suctioning
Number of subjects: 35
Study 10392222 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal suctioning without saline
Number of subjects: 35
Study 8546551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole-trimethoprim (double-strength tablet three times a week)
Number of subjects: 100
Study 8546551 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone (100 mg daily)
Number of subjects: 100
Study 8546551 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (dose not specified)
Number of subjects: 100
Study 8546551 — intervention group
Group type: COMPARATOR
Intervention: Oral regimens (compared to aerosolized pentamidine)
Number of subjects: 100
Study 8546551 — intervention group
Group type: COMPARATOR
Intervention: Different regimens (general comparison)
Number of subjects: 100
Study 2071316 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric balloon only
Number of subjects: 86
Study 2071316 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric balloon and prescribed 1000 kcal/day diet
Number of subjects: 86
Study 2071316 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 kcal/day diet only
Number of subjects: 86
Study 2071316 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 86
Study 6665832 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation for 69 days
Number of subjects: 204
Study 6665832 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation for 47 days
Number of subjects: 204
Study 6665832 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 69 days
Number of subjects: 204
Study 6665832 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 47 days
Number of subjects: 204
Study 30993591 — intervention group
Group type: EXPERIMENTAL
Intervention: Bully-victim category
Number of subjects: 471
Study 30993591 — intervention group
Group type: COMPARATOR
Intervention: Neutrals
Number of subjects: 471
Study 30993591 — intervention group
Group type: EXPERIMENTAL
Intervention: Bully-victims
Number of subjects: 471
Study 30993591 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of bullying problems
Number of subjects: 471
Study 28600725 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone DETERx
Number of subjects: 52
Study 28600725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 26923083 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinvaxem in cPAD injection system
Number of subjects: 400
Study 26923083 — intervention group
Group type: COMPARATOR
Intervention: Quinvaxem in single-dose vial
Number of subjects: 400
Study 26923083 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (cPAD and single-dose vial)
Number of subjects: 400
Study 25066559 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 4372
Study 25066559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4372
Study 21960048 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy plus exercise for ten sessions
Number of subjects: 60
Study 21960048 — intervention group
Group type: COMPARATOR
Intervention: Physical modalities plus exercise
Number of subjects: 60
Study 19093148 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable metal stents (AMSs)
Number of subjects: 117
Study 19093148 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 117
Study 19093148 — intervention group
Group type: COMPARATOR
Intervention: PTA alone
Number of subjects: 117
Study 19093148 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA followed by AMS implantation
Number of subjects: 117
Study 19080533 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with salmeterol/fluticasone (50/250 microg) twice daily and tiotropium 18 microg once daily (n = 33, M/F: 23/10)
Number of subjects: 126
Study 19080533 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with salmeterol/fluticasone and tiotropium
Number of subjects: 126
Study 19080533 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone (50/250 microg) twice daily (n = 32, M/F: 24/8)
Number of subjects: 126
Study 19080533 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18 microg once daily (n = 32, M/F: 23/9)
Number of subjects: 126
Study 19080533 — intervention group
Group type: COMPARATOR
Intervention: Blank control group (n = 29, M/F: 22/7)
Number of subjects: 126
Study 15680826 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG + ventral cardiac denervation (group B)
Number of subjects: 70
Study 15680826 — intervention group
Group type: COMPARATOR
Intervention: CABG (group A)
Number of subjects: 70
Study 12118027 — intervention group
Group type: COMPARATOR
Intervention: PVI 5-FU (300 mg/m²/d for a maximum of 24 weeks)
Number of subjects: 208
Study 12118027 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI 5-FU plus MMC (7 mg/m² every 6 weeks for four courses)
Number of subjects: 208
Study 12118027 — intervention group
Group type: COMPARATOR
Intervention: PVI 5-FU
Number of subjects: 208
Study 12118027 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI 5-FU plus MMC
Number of subjects: 208
Study 10096482 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous mitral balloon valvuloplasty (PMV)
Number of subjects: 19
Study 10096482 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal coronary arteries and LV function)
Number of subjects: 19
Study 7586111 — intervention group
Group type: EXPERIMENTAL
Intervention: TOF monitoring (Group A; n = 20)
Number of subjects: 39
Study 7586111 — intervention group
Group type: COMPARATOR
Intervention: No TOF monitoring (Group B; n = 19)
Number of subjects: 39
Study 2303688 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency sclerotherapy (1‐6 h after presentation)
Number of subjects: 84
Study 2303688 — intervention group
Group type: COMPARATOR
Intervention: Delayed sclerotherapy (more than 24 h from presentation)
Number of subjects: 84
Study 2303688 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency sclerotherapy with larger volumes of sclerosant (mean of 26 ml)
Number of subjects: 84
Study 2303688 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency sclerotherapy
Number of subjects: 84
Study 7374618 — intervention group
Group type: EXPERIMENTAL
Intervention: oxygen-multistep-therapy
Number of subjects: 14
Study 30882562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (Girls on the Move)
Number of subjects: 1519
Study 30882562 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1519
Study 27919633 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose inactivated influenza vaccine (HD IIV)
Number of subjects: 50
Study 27919633 — intervention group
Group type: COMPARATOR
Intervention: Standard dose inactivated influenza vaccine (SD IIV)
Number of subjects: 50
Study 26391700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate/ethinyloestradiol with metformin
Number of subjects: 445
Study 26391700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate/ethinyloestradiol without metformin
Number of subjects: 445
Study 26391700 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 445
Study 26391700 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS without insulin resistance (IR)
Number of subjects: 445
Study 24459172 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented exercises with early full weight-bearing
Number of subjects: 100
Study 24459172 — intervention group
Group type: COMPARATOR
Intervention: Open chain kinetic exercises with partial weight-bearing and walking aids
Number of subjects: 100
Study 21780053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp dissection with knife or scissors and excision and ligation of scar tissue using absorbable suture material
Number of subjects: 36
Study 21780053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissection with electrocoagulation
Number of subjects: 36
Study 21780053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissection with ultrasound (Ultracision Harmonic Scalpel)
Number of subjects: 36
Study 21780053 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 18719045 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg/kg THC
Number of subjects: 24
Study 18719045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17499398 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (0.3g/kg/day)
Number of subjects: 102
Study 17499398 — intervention group
Group type: COMPARATOR
Intervention: Control (isonitrogenous placebo supplementation)
Number of subjects: 102
Study 17499398 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (glutamine and control)
Number of subjects: 102
Study 17499398 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 102